See more : Castings P.L.C. (CGS.L) Income Statement Analysis – Financial Results
Complete financial analysis of Shandong Kexing Bioproducts Co,.Ltd (688136.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shandong Kexing Bioproducts Co,.Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Camurus AB (publ) (CAMX.ST) Income Statement Analysis – Financial Results
- United Community Banks, Inc. (UCBIO) Income Statement Analysis – Financial Results
- Mountain & Co. I Acquisition Corp. (MCAAU) Income Statement Analysis – Financial Results
- Concord Medical Co., Ltd. (6518.TWO) Income Statement Analysis – Financial Results
- Copperstone Resources AB (COPP-B.ST) Income Statement Analysis – Financial Results
Shandong Kexing Bioproducts Co,.Ltd (688136.SS)
About Shandong Kexing Bioproducts Co,.Ltd
Shandong Kexing Bioproducts Co., Ltd. engages in the research and development, production, and sale of recombinant protein therapeutics and microbiota agents. Its products include recombinant human erythropoietin injections, recombinant human interferon a1b injections, recombinant human granulocyte stimulating factor injections, and clostridium butyricum double live bacteria powder and capsules. The company was founded on August 22, 1997 and is headquartered in Jinan, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.26B | 1.32B | 1.29B | 1.22B | 1.19B | 890.61M | 615.84M |
| Cost of Revenue | 370.31M | 324.16M | 264.62M | 244.27M | 219.95M | 168.24M | 129.12M |
| Gross Profit | 888.72M | 991.71M | 1.02B | 976.02M | 970.81M | 722.37M | 486.72M |
| Gross Profit Ratio | 70.59% | 75.37% | 79.41% | 79.98% | 81.53% | 81.11% | 79.03% |
| Research & Development | 344.80M | 193.30M | 122.95M | 60.11M | 46.17M | 42.68M | 32.35M |
| General & Administrative | 7.69M | 28.44M | 29.90M | 20.05M | 22.72M | 54.08M | 9.35M |
| Selling & Marketing | 619.96M | 827.73M | 755.60M | 655.54M | 647.22M | 468.08M | 327.65M |
| SG&A | 627.66M | 856.17M | 785.50M | 675.59M | 669.94M | 522.16M | 337.01M |
| Other Expenses | 175.06M | 62.05M | 66.35M | 56.54M | 44.81M | -1.69K | -14.70M |
| Operating Expenses | 1.15B | 1.11B | 974.80M | 792.24M | 760.92M | 580.34M | 386.18M |
| Cost & Expenses | 1.52B | 1.44B | 1.24B | 1.04B | 980.87M | 748.58M | 515.30M |
| Interest Income | 6.64M | 7.31M | 9.06M | 937.64K | 345.96K | 221.09K | 260.85K |
| Interest Expense | 41.12M | 26.31M | 8.03M | 10.33M | 6.67M | 11.16M | 6.69M |
| Depreciation & Amortization | 88.26M | 81.01M | 56.63M | 33.69M | 12.89M | 9.39M | 8.20M |
| EBITDA | -132.68M | -28.87M | 164.81M | 209.75M | 213.90M | 143.82M | 89.66M |
| EBITDA Ratio | -10.54% | -2.71% | 8.21% | 16.52% | 19.14% | 18.18% | 16.40% |
| Operating Income | -254.20M | -119.81M | 55.57M | 159.85M | 188.98M | 121.27M | 89.32M |
| Operating Income Ratio | -20.19% | -9.10% | 4.32% | 13.10% | 15.87% | 13.62% | 14.50% |
| Total Other Income/Expenses | -5.87M | -19.26M | 40.06M | -19.40M | -11.89M | -1.69K | -24.11M |
| Income Before Tax | -260.07M | -139.06M | 95.63M | 159.16M | 187.78M | 121.27M | 74.62M |
| Income Before Tax Ratio | -20.66% | -10.57% | 7.44% | 13.04% | 15.77% | 13.62% | 12.12% |
| Income Tax Expense | -64.58M | -46.24M | -836.85K | 20.02M | 27.97M | 27.10M | 15.23M |
| Net Income | -190.29M | -92.82M | 96.46M | 139.14M | 159.81M | 94.16M | 59.39M |
| Net Income Ratio | -15.11% | -7.05% | 7.51% | 11.40% | 13.42% | 10.57% | 9.64% |
| EPS | -0.96 | -0.47 | 0.49 | 0.70 | 0.80 | 1.54 | 0.97 |
| EPS Diluted | -0.96 | -0.47 | 0.49 | 0.70 | 0.80 | 1.54 | 0.97 |
| Weighted Avg Shares Out | 198.22M | 198.70M | 198.70M | 198.70M | 198.70M | 61.15M | 61.23M |
| Weighted Avg Shares Out (Dil) | 198.22M | 198.70M | 198.70M | 198.70M | 198.70M | 61.15M | 61.23M |
Source: https://incomestatements.info
Category: Stock Reports